Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: Focus on amlodipine/olmesartan combination

Drugs of Today

Volumn 44, Issue 6, 2008, Pages 443-453

  Chrysant, Steven G ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL MALEATE; ENALAPRIL MALEATE PLUS FELODIPINE; FELODIPINE; HYDRALAZINE PLUS HYDROCHLOROTHIAZIDE PLUS RESERPINE; OLMESARTAN; PLACEBO; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; VALSARTAN; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG WITHDRAWAL; EDEMA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERTENSION; INCIDENCE; INFECTION; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; PRACTICE GUIDELINE; REVIEW; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; HYPERTENSION; MIDDLE AGED;

EID: 49149110125     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.6.1223895     Document Type: Review

References (39)

1. Ong, K.L., Cheung, B.M., Man, Y.B. et al. Prevalence, awareness, treatment and control of hypertension among United States adults 1999-2004. Hypertension 2007, 49(1): 69-75.
2. Chobanian, A.V., Bakris, G.L., Black, H.R. et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC7 report. Hypertension 2003, 42(6): 1206-52.
3. Materson, B.J., Reda, D.J., Cushman, W.C. et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993, 328(13): 914-21.
4. Mancia, G., DeBaker, G., Dominiczak, A. et al. 2007 ESH-ESC Practice guidelines for the management of arterial hypertension. J Hypertens 2007, 25(9): 1751-62.
5. Ram, CV. Antihypertensive efficacy of the angiotensin receptor blockers in combination with hydrochlorothiazide: A review of the factorialdesign studies. J Clin Hypertens (Greenwich) 2004, 6(10): 569-77.
6. Chrysant, S.G. Fixed low-dose drug combination for the treatment of hypertension. Arch Fam Med 1998, 7(4): 370-6.
7. Messerli, F.H. Combination therapy in hypertension. J Hum Hypertens 1992, 6(Suppl. 2): S19-21.
8. Epstein, M., Bakris, G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996, 156(17): 1969-78.
9. Sica, D.A. Fixed-dose combination anti-hypertensive drugs. Do they have a role in rational therapy? Drugs 1994, 48(1): 16-24.
10. Gradman, A.H., Cutler, N.R., Davis, P.J. et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril - Felodipine ER Factorial Study Group. Am J Cardiol 1997, 79(4): 431-5.
11. Chrysant, S.G., Cohen, M. Sustained blood pressure control with controlled release isradipine. Am J Hypertens 1995, 8(1): 87-9.
12. Chrysant, S.G., Marbury, T.C., Robinson, T.D. Antihypertensive efficacy and safety of olmesartan medoxomil compared to amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003, 17(6): 425-32.
13. Chrysant, S.G., Bakris, G.L. Amlodipine/benazepril monotherapy. Am J Hypertens 2004, 17(7): 590-6.
14. Fogari, R., Zappi, A., Derosa, G. et al. Effect of valsartan addition to amlodipine on ankle edema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007, 21(3): 220-4.
15. Messerli, F.H. Vasodilatory edema: A common side effect of antihypertensive therapy. Am J Hypertens 2001, 14(9, Pt. 1): 978-9.
16. Ausubel, H., Levine, M.L. Treatment of hypertension with Ser-Ap-Es. Curr Ther Clin Exp 1967, 9(1): 29-35.
17. Chrysant, S.G., Gavras, H., Niederman, A.I. et al. Clinical utility of long-term enalapril/diltiazem ER in stage 3-4 essential hypertension. J Clin Pharmacol 1997, 37(9): 810-5.
18. Dequattro, V., Lee, D., Messerli, F.H. Fixed-dose combination therapy with trandolapril and verapamil SR in primary hypertension: A 4x4 trial design. The Trandolapril Study Group. Clin Exp Hypertens 1999, 19(3): 373-87.
19. Chrysant, S.G., Sugimoto, D.H., Lefkowitz, M. et al. The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Blood Press 2007, 16(Suppl. 1): 10-7.
20. Philipp, T., Smith, T.R., Glazer, R. et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007, 29(4): 563-80.
21. Chrysant, S.G., Melino, M., Karki, S., Lee, J., Heyrman, R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8 week factorial efficacy and safety study. Clin Ther 2008, 30(4): 587-604.
22. Moser, M. From JNC1 to JNC7. What have we learned? Prog Cardiovasc Dis 2006, 48(5): 303-15.
23. Fagan, T.C Remembering the lessons of basic pharmacology. Arch Intern Med 1994, 154(13): 1430-1.
24. Okonofua, E.C., Simpson, K.N., Jesri, A. et al. Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals. Hypertension 2006, 47(3): 345-51.
25. Rose, A.J., Berlowitz, D.R., Orner, M.B. et al. Understanding uncontrolled hypertension: Is it the patient or the provider? J Clin Hypertens 2007, 9(12): 937-43.
26. Lewington, S., Clarke, R., Qizibash, N., Peto, R., Collins, R.; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data from one million adults in 61 prospective studies. Lancet 2002, 360(9349): 1903-13.
27. Oparil, S., Williams, D., Chrysant, S.G. et al. Comparison of efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens 2001, 3(5): 283-91.
28. Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288(23): 2981-97.
29. Julius, S., Kjeldsen, S.E., Weber, M.A. et al. Outcomes in hypertensive patients at high risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 2004, 363(9426): 2022-31.
30. Chrysant, S.G., Dimas, B., Shiraz, M. Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: An update. J Hum Hypertens 2007, 21(9): 699-708.
31. Chrysant, S.G., Chrysant, G.S. Clinical experience with angiotensin receptor blockers with particular reference to valsartan. J Clin Hypertens 2004, 6(8): 445-51.
32. Dahlof, B., Devereux, R.B., Kjeldsen, S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint (LIFE) reduction hypertension study: A randomized trial against atenolol. Lancet 2002, 359(9311): 995-1003.
33. Kjeldsen, S.E., Dahlof, B., Devereux, R.B. et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention For Endpoint (LIFE) sub-study. JAMA 2002, 288(12): 1491-8.
34. Lithell, H., Hansson, L., Skoog, I. et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21(5): 875-86.
35. Papademetriou, V., Farsang, C., Elmfeldt, D. et al. Stroke prevention with the angiotensin-II type 1 receptor blocker candesartan in elderly patients with isolated systolic hypertension: The Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004, 44(6): 1175-80.
36. Schrader, J., Luders, S., Kulschewski, A. et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized control study (MOSES). Stroke 2005, 36(6): 1218-26.
37. Chrysant, S.G. Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today (Bare) 2004, 40(9): 791-801.
38. Chrysant, S.G. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: Clinical and experimental evidence. J Hum Hypertens 2005, 19(12): 923-31.
39. Chrysant, S.G., Chrysant, G.S. The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens 2006, 8(4): 261-8.